-+ 0.00%
-+ 0.00%
-+ 0.00%

ST Wanbang announced that its wholly-owned subsidiary Wanbang Pharmaceutical Group Co., Ltd. independently developed the new drug WP107 for the treatment of systemic myasthenia gravis, and recently obtained approval from the US Food and Drug Administration for multi-dose slope climbing clinical trial studies for health trial participants.

Zhitongcaijing·07/16/2026 09:49:08
Listen to the news
ST Wanbang announced that its wholly-owned subsidiary Wanbang Pharmaceutical Group Co., Ltd. independently developed the new drug WP107 for the treatment of systemic myasthenia gravis, and recently obtained approval from the US Food and Drug Administration for multi-dose slope climbing clinical trial studies for health trial participants.